The standard of playing interferon clinical cure is divided into two different situations, namely, hepatitis III patients and hepatitis III patients. 1. patients with hepatitis B: interferon is a nucleotide drug, according to China’s hepatitis B prevention and treatment guidelines, patients with hepatitis B using nucleotide drugs should be more than four years of treatment, the virus quantitative test is lower than 1000IU/mL, liver function is normalized, and hepatitis B is transformed into hepatitis B. At this time, the clinical cure standard is reached, but still need to use long-term medication for at least three years, so as to avoid viral recurrence. 2. Patients with hepatitis minor triple positive: for this kind of patients to reach the clinical cure standard, it is also necessary for the quantitative detection of virus to be lower than the lower limit, the liver function to return to normal, indicating that the antigen has turned to be negative, and it is still necessary to consolidate for about one year before the clinical cure standard can be reached. Because of the large side effects of interferon and the low efficiency, the use of interferon for treatment should be carried out under the guidance of a physician.